TrialActa haematologica2019

Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Sanford Kempin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.